Open Access

Seprafilm® adhesion barrier: (1) a review of preclinical, animal, and human investigational studies

  • Michael P. Diamond1Email author,
  • Ellen L. Burns2,
  • Beverly Accomando2,
  • Sadiqa Mian2 and
  • Lena Holmdahl2
Gynecological SurgeryEndoscopic Imaging and Allied Techniques20129:741

https://doi.org/10.1007/s10397-012-0741-9

Received: 11 January 2012

Accepted: 13 February 2012

Published: 20 April 2012

Abstract

The aim of this study was to provide a single site resource for investigators, clinicians, and others seeking preclinical, animal, and human investigational studies concerning the postsurgical, anti-adhesion barrier Seprafilm™ (Genzyme Corporation, Cambridge, MA). All published preclinical, animal, human extra-abdominal research as of July 2011 have been summarized and included in this document. Searches of Medline and EMBASE Drugs and Pharmaceuticals databases were conducted for original preclinical, animal, and human extra-abdominal studies involving Seprafilm. Preclinical, animal, and extra-abdominal human investigational studies are the study selection for this manuscript. Intraabdominal use is discussed in the accompanying manuscript. Data extraction includes systematic manuscript review. Summary of preclinical, animal, and extra-abdominal human investigational use of Seprafilm by surgical discipline were gathered for data synthesis. The clinical use of Seprafilm, which was approved by the FDA for intra-abdominal procedures, is supported by preclinical and animal studies relating to general surgical and obstetrical/gynecological applications. Findings from preclinical, animal, and human investigational studies at other sites throughout the body raises the potential for additional human clinical trials to assess efficacy and safety following surgical procedures at non-abdominal locations.

Keywords

Postoperative adhesions Seprafilm Anti-adhesion adjuvant Adhesiolysis

Introduction

Postoperative adhesions lead to significant patient morbidity such as small bowel obstruction, infertility, chronic pain, and difficult, complicated subsequent surgeries. Various strategies have been put forth to prevent adhesion development including meticulous surgical techniques, pharmacological agents, and new equipment and instrumentation. Yet, despite these interventions, the overwhelming majority of patients continue to develop adhesions after surgical procedures.

Pathogenesis of adhesions

Considerations for adhesion prevention should be based upon an understanding of peritoneal repair, and what goes awry when adhesions develop, as briefly summarized below [13]. Postoperative adhesion development is teleologically considered to be an effort by the body to restore the supply of oxygen and nutrients to tissue which has been injured during the surgical procedure. As a sequelae to tissue injury, an inflammatory-like response occurs in response to surgery-induced tissue hypoxia, with resultant generation of reactive oxygen and reactive nitrogen species. This inflammatory response invokes release of histamine, cytokines, and growth factors; infiltration of polymorphonuclear leukocytes; and the migration of fibroblasts from underlying tissues. Collections of blood and serosanguinous tissue exudates occur on the surface of injured tissue forming a fibrinous mass. In the presence of diminished or absent tissue plasminogen activator activity, the fibrinous mass persists long enough for infiltration by the migrating fibroblasts from the underlying tissues, with subsequent deposition of extracellular matrix including collagen and fibronectin. Persistence of relative hypoxia induces vascular endothelial growth production with subsequent angiogenesis. This process persists during and beyond the 3 to 5 days required for remesotheliazation of injured tissue surfaces.

If this concept of adhesion development is correct, then the critical time to prevent or diminish adhesion development is in the initial 3 to 5 days after the surgical procedure, prior to completion of remesotheliazation. Additionally, adjuvants and approaches to reduce adhesions would either interrupt the molecular biologic process leading to adhesion development and/or physically separate opposing tissue surfaces at risk for adhesion development until after remesotheliazation is complete. It is this latter approach which has been utilized by all of the FDA-approved devices for the reduction of postoperative intra-abdominal and pelvic adhesions, including Seprafilm. This manuscript summarizes the preclinical, animal, and human investigational studies involving Seprafilm. A companion manuscript summarizes reports of intra-abdominal use of Seprafilm for general surgical and gynecological operative procedures.

Seprafilm adhesion barrier

Physical properties and clearance

Seprafilm is a bioresorbable membrane composed of sodium hyaluronate (HA) and carboxymethylcellulose (CMC) which have been chemically modified to delay the rate of degradation and clearance after placement in the body. Seprafilm is applied to the surface of tissues to be protected and hydrates to form a lubricious gel coating within 24 to 48 h of placement. The hydrophilic protective gel acts as physical barrier to separate adjacent serosal tissues during the critical stages of wound repair and has no pharmacological effect. During the transition from a solid to gel, the volume of the barrier increases, but its swelling pressure decreases from 6.4 atm to 0. In addition, Seprafilm’s tensile strength decreases by 90 % within 30 min. The membrane’s swelling does not affect peritoneal tissue or organ function. The barrier is resorbed from the site of application within 7 days and therefore does not require a second operation for removal. Radiolabeled studies of Seprafilm showed that it is totally cleared from the body within 28 days following implantation. Seprafilm is excreted primarily through the kidneys. Seprafilm’s rapid degradation reduces the risk of a foreign body tissue response [4].

Preclinical safety and efficacy studies

The safe and effective use of Seprafilm in the abdominal cavity of animals has been reported in a number of publications using multiple species and models of abdominal surgery [434]. In these models, the use of Seprafilm was reported to be efficacious in reducing adhesions, including in the presence of blood and irrigation solution [4], in combination with melatonin [33] and under ischemic conditions [4]. When used in multiple layers [4], Seprafilm did not adversely affect wound healing [4, 6, 8, 35], did not affect anastomotic healing with [36] or without concomitant ischemia [35, 37], and did not potentiate intra-abdominal sepsis [11, 38]. In general, Seprafilm use has been reported not to have adverse effects [5, 7, 9, 10, 12, 13, 3941]. Concomitant radiotherapy did not alter the efficacy [42]; however, the efficacy of Seprafilm was reduced in the presence of peritonitis [43].

In addition, the use of Seprafilm in animal models has been reported from a number of anatomical sites outside of the abdominal cavity, including following nerve repair [44] and cancer treatment [4548]. In this series of articles, the application of Seprafilm did not increase cancer cell growth, wound site implantation, or distant metastasis and did not decrease host survival. Additionally, Seprafilm has been reported to be safe and beneficial when used in conjunction with cardiac surgery [4951], tendon surgery [52], joint surgery [53], spinal surgery [5456], strabismus surgery [57], and tympanic membrane surgery [58].

Multiple preclinical safety studies in various animal models have been conducted to assess the immunogenicity, biocompatibility, and tissue response to Seprafilm [4]. Dermal and systemic immunogenicity (using sodium hyaluronate–carboxymethylcellulose (HA-CMC) extracts) were studied with two series of intradermal injections in 15 adult albino guinea pigs, and by six intraperitoneal injections in ten adult guinea pigs over a period of 2 weeks followed by an intravenous challenge injection, respectively [4]. Dermal injection sites were observed for erythema and edema over a 96-h period; no indications of dermal sensitization were observed. In addition, no systemic response suggestive of antigenecity or anaphylaxis was observed after multiple intraperitoneal injections followed by an intravenous challenge injection.

Biocompatibility was assessed through studies of in vitro hemolysis, in vitro complement activation, in vitro cytotoxicity, and muscle implant tests [4]. In all cases, Seprafilm did not elicit reactions suggestive of tissue incompatibility. Tissue response to Seprafilm was examined in a rat model by abrading the rat cecum, followed by either the application of Seprafilm (treatment group) or no further intervention (untreated group). Animals were observed for 28 days; inflammatory cells including macrophages were noted at day 2 in both groups. At day 4, a large number of macrophages (no giant cells) were observed in the treatment group suggestive of HA-CMC degradation, while the untreated group displayed fewer macrophages and occasional polymorphonuclear cells, suggestive of the normal wound healing process. At day 28, the rat cecum appeared to be healed in both groups, but the untreated group had denser granulation tissue at the wound site. Additionally, the Ames mutagenicity test, the rabbit pyrogen test, the intracutaneous toxicity test, and the acute intraperitoneal and systemic toxicity tests, respectively demonstrated that Seprafilm is biocompatible, non-mutagenic, non-pyrogenic, non-irritating, and nontoxic [4].

Preclinical evaluation of the efficacy of Seprafilm in a rat cecal abrasion or side wall injury model demonstrated that Seprafilm significantly reduced the incidence of cecal adhesions (P < 0.001) and the number of animals with severe adhesions (P < 0.001) when compared with non-treated controls [4]. This efficacy was maintained in the presence of blood, excess irrigation fluids, and layering of Seprafilm, as well as under ischemic conditions. Subsequently, in cell culture studies of human peritoneal and adhesion fibroblasts, Seprafilm was not observed to alter expression of inflammatory markers such as type I collagen and transforming growth factor beta [59].

Efficacy of Seprafilm has also been demonstrated in an adhesion reformation model [33]. In this study, adhesion reformation was induced between the uterine horns by creation of ten standardized lesions on the uterine horns using bipolar electrocoagulation, with separation from tissue lying above and below with Seprafilm. Adhesiolysis was performed at the time of a second-look procedure with randomization to one of four groups: control, Seprafilm alone, melatonin (a free radical scavenger) alone (1 ml of a 2-mg/ml solution), or a combination of Seprafilm plus melatonin. At the time of a third-look procedure, adhesion reformation was significantly reduced by either Seprafilm or melatonin alone compared to control animals, with a further significantly greater reduction in adhesion reformation achieved with the combination of Seprafilm plus melatonin [33].

Use of Seprafilm with specific conditions

Infection

The effect of Seprafilm on abscess development was studied in three independent animal studies in which Seprafilm was placed in the presence of existing peritonitis. In two of those studies, Seprafilm had no effect on abscess development [60] while in a third study Seprafilm was associated with increased abscess development when placed in the presence of ongoing peritonitis [43]. Although these results are inconsistent, the Seprafilm label directs users not to use the product in the presence of frank infection. Additional work in experimental models have shown that Seprafilm had no effect on sepsis or abscess development when Seprafilm placement was concomitant with bacterial contamination [38] when placed in a surgical model of bowel injury [11] and that it did not exaggerate intra-abdominal septic conditions or induce a systematic inflammatory response [61].

To further elucidate mechanistic aspects of the possible impact of Seprafilm on infectious processes, Otake et al. examined the effect of Seprafilm in polymorphonuclear (PMN) obtained from 14 subjects [62]. Seprafilm was evaluated in two forms, as a film and after it was well dissolved and compared to corresponding controls. Seprafilm, in either form, had no effect on the rate of phagocytosis of Escherichia coli or Staphylococcus aureus, the rate of PMN-induced apoptosis of E. coli and S. aureus, and the effect of PMN-induced necrosis of E. coli and S. aureus. Examining cytokine production when co-cultured with E. coli or S. aureus, Seprafilm also had no effect on production of the cytokines IL-1α, IL-6, or IL-8 or on the production of IL-1 RA or PMN elastase. There was also no effect on PMN cytokine production when stimulated with TNF-α or LPS.

Malignancy

In vitro studies did not find any increase in the growth of colon cancer cells when cultured in the presence of Seprafilm [45]. Preclinical studies in mouse or hamster models did not observe any increase in cancer cell growth, wound site implantation, distant metastasis, or host survival with the use of Seprafilm in the presence of cancer cells, when compared with the control [4648].

Animal investigational studies of use of Seprafilm

Cardiac surgery

Preclinical studies in dogs, pigs, sheep, and rabbits evaluating the use of Seprafilm in cardiac surgery observed a significant decrease in the severity of pericardial adhesions in most [4951, 63], but not all studies [64].

Thoracic surgery

A preclinical study in sheep was done to assess the effect of Seprafilm on pleural adhesion formation after experimental thoracotomy and parietal pleurectomy [65]. A significant decrease in the incidence (P < 0.001) and severity (P < 0.001) of the pleural adhesions was noted in the Seprafilm group when compared with control. There was no increase in inflammation in the areas of Seprafilm application. A preclinical study in rats was unable to identify a benefit or detriment when the esophagus was wrapped with Seprafilm or Interceed, as assessed by adhesion score 3 weeks later or by hyroxyproline levels [66].

Vascular surgery

To investigate whether external support would reduce intimal hyperplasia at the site of venous graft anastamosis, rabbits undergoing bypass grafting of the right jugular vein to the right common carotid artery was performed in the presence or absence of wrapping the anastamosis with Seprafilm [67]. Evaluation at 1 month demonstrated that use of Seprafilm reduced both neointimal and medial thickening.

Orthopedic surgery

In a preclinical study, Seprafilm was used to prevent adhesions after tenolysis at the flexor digitorum tendon in chickens [52]. Six weeks after the application of Seprafilm, tendons that received Seprafilm were seen to have a significantly improved gliding excursion profile (P < 0.05) and decreased incidence of adhesions (P < 0.05), when compared with controls. Consistent results were observed in a chicken gastrocnemius tendon model, in which Seprafilm wrapping resulted in improved tendon sheath complex sliding, less histological evidence of tissue inflammation, and greater tendon tensile strength, as compared to untreated controls [68]. Similarly, in a rabbit partial-thickness flexor tendon injury–suture repair model, comparing Seprafilm and other HA-based products versus controls, there was a reduction in both the gross adhesion score and the histologic adhesion score and an improvement in histologic assessment of tender healing [69]. In a biomechanical test, the force required to remove the tendon from its sheath was less for Seprafilm than injured, untreated control animals.

The safety of Seprafilm use in femorotibial joints was studied in adult female New Zealand White rabbits [53]. Intraarticular administration of Seprafilm in femorotibial joints of rabbits was associated with transient uptake by synovial phagocytes, but no local toxicity was apparent for up to 6 months.

Three studies have evaluated Seprafilm after laminectomy. The first preclinical study compared the effect of Seprafilm and GORE-TEX membrane in preventing peridural fibrosis after spinal surgeries in rats [55]. Seprafilm or Gore-Tex was applied to a laminectomy defect overlying the dura mater and evaluated 2 months later. Both membranes facilitated access to the epidural space and provided a reduction in the amount of tissue adhering to the dura mater. There was a statistically significant decrease in the peridural adhesions with the use of Seprafilm when compared with the Gore-Tex membrane. The second study evaluated rats that underwent hemilaminectomy at L4 and L5 followed by treatment with Seprafilm or Interceed [56]. Both agents significantly reduced epidural fibrosis and dural adhesions at 4 and 8 weeks evaluation. The third study compared ADCON-L to Seprafilm in a rat laminectomy model. Both products were found to be effective in reducing peridural adhesions [54].

Seprafilm has also been evaluated to determine its effects on peripheral nerves, in models, both with and without nerve injury [70]. In the former, Seprafilm was placed either superficially to the nerve or wrapped circumferentially around the nerve. In both cases, Seprafilm had no effect on the nerve at evaluation times up to 6 weeks, as assessed by nerve compression, nerve fibrosis or inflammation, foreign body reaction, or nerve ultrastructure, vascularity, and histomorphology. It was also noted that there were qualitatively fewer adhesions at the operative site, with preservation of the surgical plane medial to the gluteal muscle. In the nerve injury model in which the sciatic nerve was severed and then repaired, Seprafilm treatment was associated with less perinural adhesions. The histomorphological findings favored Seprafilm at the initial evaluation period (18 days) and control at the final evaluation period (42 days), although no functional outcome differences were identified [70].

Opthalmic surgery

In a preclinical study, Seprafilm has been used to prevent conjunctival adhesions after strabismus surgery [57]. Seprafilm was applied to the eyes of New Zealand rabbits after dissection in the area of the superior fornix and inferior conjunctival limbus. Six weeks after the initial procedure, eyes in which Seprafilm was applied showed significantly less fibrosis, both at the area of superior rectus resection (P < 0.046) and the area of conjunctival dissection (P < 0.015) as compared to the control areas. No increase in inflammation was observed at the areas of application of Seprafilm. In other ophthalmic studies, adhesion development in rabbits was reduced by Seprafilm after creation of either conjunctival flaps or when applied above and below scleral flaps [71]. Additionally, Seprafilm application in subconjuctival pockets was associated with a reduction in the mean adhesive force between the sclera and conjunctiva, while placement of Seprafilm on the scleral flap after trabeculectomy resulted in a larger subconjuctival space and reduced intraocular pressure as compared to control rabbits [72]. Seprafilm was subsequently used experimentally for patching of small retinal breaks in a rabbit model of rhegmatogenous retinal detachment [73]. In treated animals, retinal reattachments were identified, as contrasted to proliferative vitreoretinopathy in the control group.

Otologic surgery

Adhesions in the middle ear can contribute to conductive hearing loss, as well as tympanic membrane retraction. In a study of guinea pigs, abrasion of the middle ear mucosa through a myringotomy incision was used to create adhesions and evaluate their reduction by Seprafilm [74]. In contrast to control animals, those that had received Seprafilm packing at the conclusion of the surgical procedure had no middle ear cleft adhesions and no differences in auditory brainstem responses at 3 or 6 weeks after surgery [74].

Human investigational uses of Seprafilm

Intrauterine

In a prospective, blinded, randomized, controlled study, Seprafilm was studied for adhesion prevention after the suction and/or curettage evacuation of the uterus in 150 women (Table 1) [75]. Seprafilm was applied following the procedure. One Seprafilm membrane was cut into two equal pieces, then rolled and inserted through the end cervical canal into the endometrial cavity. The end point of the study was pregnancy or demonstration of adhesions on hysterosalpingography. Among the women with no prior history of dilatation and curettage (D&C), 100 % of Seprafilm-treated women achieved pregnancy within 8 months of the procedure, compared with 54 % of the control women who became pregnant during the same interval of time. Of the women with prior history of D&C, 33 % of the Seprafilm-treated women and 22.7 % of the control women became pregnant. Hysterosalpingography in women, who had not become pregnant, revealed adhesions in 10 % of the Seprafilm-treated women and 50 % of the control group of women.
Table 1

Investigational clinical publications and calculated effect size

Reference

N

Therapeutic area

Favorable Seprafilm outcome

Effect sizea

Reported p value

van der Linden. [76]

19

Cardiac

Median retrosternal adhesions

Cannot be calculated, only median and range reported

NS

Koyuncu et al. [78]

23

Vascular

Internal jugular vein function

n/a

NS

Tsapanos et al. [75]

150

Gynecologic

Incidence of adhesions

2.9

Not reported

Intrauterine surgery

Pregnancies

4.8

Sanders et al. [77]

249

Neurologic

15 year old historical control group

  

Successful primary scalenectomy

0.9

0.938

Successful primary scalenectomy/1st rib resection

0.7

0.634

Successful reoperation: neurolysis

1.3

0.760

Successful reoperation: scalenectomy and neurolysis

1.6

0.811

Icinose et al. [84]

n/a

Neurologic

No control group or efficacy

n/a

n/a

Assaf et al. [80]

4

Opthalmic

No control group or efficacy

n/a

n/a

Taban et al. [81]

4

Opthalmic

No control group or efficacy

n/a

n/a

Shibata et al. [82]

1

Opthalmic

No control group

n/a

n/a

Filler et al. [79]

239

Orthopedic

No safety, efficacy or control

n/a

n/a

Caylan et al. [83]

21

Otologic

No control group

n/a

n/a

aFor continuous outcomes, effect size is the (control group mean–the Seprafilm mean) divided by the pooled standard deviation for the two groups [ES = (M1−M2)/pooled SD], and for binomial outcomes, effect size is the odds ratio or the ratio of the odds of a success for the Seprafilm group to the odds of a success for the control group [ES = (ad)/(bc)]

Cardiac surgery

In a prospective clinical study in patients undergoing coronary artery bypass graft surgery, the median percentage of retrosternal adhesions in the group that received Seprafilm was 53 % (range 27–88 %) versus 71 % (range 18–90 %) in patients who did not receive Seprafilm. This difference was not statistically significant [76].

Thoracic surgery

Seprafilm was utilized in 249 subjects with neurogenic thoracic outlet syndrome [77]. The barrier was placed over the fine nerve roots of the bronchial plexus at the conclusion of the supraclavicular thoracic outlet decompression procedure, in an attempt to reduce postoperative scarring. Success rates for primary operations for scalenectomy with or without resection of the first rib was 70 and 74 %, respectively, and 78 % for reoperative procedures. These results were no different than historical controls, although reoperations demonstrated a trend towards improvement in symptoms. In ten patients who underwent reoperations, it was thought there were reduced adhesions of the fat pad to the nerve root, thereby facilitating identification of the nerve roots.

Vascular surgery

In a small study of individuals undergoing functional neck dissection, the impact of wrapping the jugular vein with Seprafilm was evaluated [78]. Three months postoperatively, Doppler ultrasound evaluation of internal jugular vein function identified no differences in the healing process.

Orthopedic surgery

Seprafilm was used as an adhesiolytic agent in patients who underwent surgical treatment for release of sciatic nerve entrapment in the pelvis or at the level of the ischial tuberosity [79]. No safety or efficacy assessments were made.

Opthalmic surgery

Seprafilm has been successfully used in four patients undergoing strabismus surgery. Seprafilm was inserted over the muscle without complication. The authors reported the application of Seprafilm to be safe in patients undergoing repeated strabismus surgery [80]. In another report, Seprafilm was applied in four subjects (six sites total) with orbital fractures and entrapped orbital soft tissue [81]. Seprafilm was placed over the fracture in these “trap doors”, with no subsequent need for reoperation and with no complications. Lastly, Seprafilm was used in one patient with neovascular glaucoma who underwent bilateral trabeculectomy. The authors reported that in this patient, trabeculotomy adjunct use of Seprafilm was effective in controlling intraocular pressure, maintenance of scleral flap, and prevention of adhesions between the scleral flap and conjunctiva [82].

Otologic surgery

In a case series of 21 patients with middle ear and or mastoid cholesteatoma, undergoing staged tympanoplasty with mastoidectomy, Seprafilm was applied in the mastoid cavity [83]. Seprafilm was reported to result in the preservation of the aeration of the mastoid cavity while preventing retraction of postauricular skin. No adverse reactions were reported.

Neurosurgery

Use of Seprafilm has been described in a series of 13 patients in whom the barrier was placed between the temporal muscle and the dura at the time of cranioplasty for external decompression for brain swelling [84]. Such use was identified by the authors as facilitating subsequent cranioplasties, by decreasing bleeding and operative time, as well as injuries to the temporal muscle or dura.

Summary

Seprafilm has been extensively studied in intraperitoneal clinical trials, demonstrating safety and efficacy in reducing postoperative adhesion development after intra-abdominal surgery. This report summarizes preclinical studies demonstrating the time course and mechanism of Seprafilm degradation. Additionally, key animal studies involving procedures both intra-abdominally and elsewhere throughout the body have been summarized, identifying efficacy and safety at these diverse locations. Results of published human investigational uses at non-abdominal locations throughout the body have also been detailed. These findings provide the opportunity for future randomized, controlled clinical trials of Seprafilm outside the intra-abdominal cavity, and also the foundation to further improve the efficacy of anti-adhesion adjuvants, perhaps by using barriers (which function separating traumatized surfaces during mesothelial repair) to also serve as a device for local delivery of drugs and/or biologics.

Declarations

Conflict of interest

Michael P. Diamond has acted as consultant to the company. The authors alone are responsible for the content and writing of the paper.

Open Access

This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

Authors’ Affiliations

(1)
Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Wayne State University
(2)
Genzyme Corporation

References

  1. Ward BC, Panitch A (2009) Abdominal adhesions: current and novel therapies. J Surg Res 165(1):91–111PubMedView ArticleGoogle Scholar
  2. Saed GM, Diamond MP (2004) Molecular characterization of postoperative adhesions: the adhesion phenotype. J Am Assoc Gynecol Laparosc 11(3):307–314PubMedView ArticleGoogle Scholar
  3. Imudia AN, Kumar S, Saed GM, Diamond MP (2008) Pathogenesis of intra-abdominal and pelvic adhesion development. Semin Reprod Med 26(4):289–297PubMedView ArticleGoogle Scholar
  4. Burns JW, Colt MJ, Burgees LS, Skinner KC (1997) Preclinical evaluation of Seprafilm bioresorbable membrane. Eur J Surg Suppl 577:40–48PubMedGoogle Scholar
  5. Greenawalt K, Masi L, Muir C, Burns J (1993) The physical properties of a hyaluronic acid based bioresorbable membrane for the prevention of post-surgical adhesions. Paper presented at Mat Res Soc Symp ProcGoogle Scholar
  6. Alponat A, Lakshminarasappa SR, Yavuz N, Goh PM (1997) Prevention of adhesions by Seprafilm, an absorbable adhesion barrier: an incisional hernia model in rats. Am Surg 63(9):818–819PubMedGoogle Scholar
  7. Avsar AF, Avsar FM, Sahin M, Topaloglu S, Vatansev H, Belviranli M (2003) Diphenhydramine and hyaluronic acid derivatives reduce adnexal adhesions and prevent tubal obstructions in rats. Eur J Obstet Gynecol Reprod Biol 106(1):50–54PubMedView ArticleGoogle Scholar
  8. Bulbuller N, Sapmaz E, Akpolat N, Ustundag B, Kirkil C (2003) Effect of a bioresorbable membrane on postoperative adhesions and wound healing. J Reprod Med 48(7):547–550PubMedGoogle Scholar
  9. Saribeyoglu K, Pekmezci S, Ulualp K (2004) Seprafilm may ease colostomy reversal. Arch Surg 139(12):1380–1382PubMedView ArticleGoogle Scholar
  10. Osada H, Minai M, Tsunoda I, Fujii TK, Tsubata K, Satoh K (1999) The effect of hyaluronic acid–carboxymethylcellulose in reducing adhesion reformation in rabbits. J Int Med Res 27(6):292–296PubMedGoogle Scholar
  11. Moreira H Jr, Wexner SD, Yamaguchi T et al (2000) Use of bioresorbable membrane (sodium hyaluronate + carboxymethylcellulose) after controlled bowel injuries in a rabbit model. Dis Colon Rectum 43(2):182–187PubMedView ArticleGoogle Scholar
  12. Hellebrekers BW, Trimbos-Kemper GC, van Blitterswijk CA, Bakkum EA, Trimbos JB (2000) Effects of five different barrier materials on postsurgical adhesion formation in the rat. Hum Reprod 15(6):1358–1363PubMedView ArticleGoogle Scholar
  13. Buckenmaier CC 3rd, Pusateri AE, Harris RA, Hetz SP (1999) Comparison of antiadhesive treatments using an objective rat model. Am Surg 65(3):274–282PubMedGoogle Scholar
  14. Yamaner S, Kalayci M, Barbaros U, Balik E, Bulut T (2005) Does hyaluronic acid–carboxymethylcellulose (HA-CMC) membrane interfere with the healing of intestinal suture lines and abdominal incisions? Surg Innov 12(1):37–41PubMedView ArticleGoogle Scholar
  15. Sahin M, Cakir M, Avsar FM, Tekin A, Kucukkartallar T, Akoz M (2007) The effects of anti-adhesion materials in preventing postoperative adhesion in abdominal cavity (anti-adhesion materials for postoperative adhesions). Inflammation 30(6):244–249PubMedView ArticleGoogle Scholar
  16. Numanoglu V, Cihan A, Salman B et al (2007) Comparison between powdered gloves, powder-free gloves and hyaluronate/carboxymethylcellulose membrane on adhesion formation in a rat caecal serosal abrasion model. Asian J Surg 30(2):96–101PubMedView ArticleGoogle Scholar
  17. Kelekci S, Uygur D, Yilmaz B, Sut N, Yesildaglar N (2007) Comparison of human amniotic membrane and hyaluronate/carboxymethylcellulose membrane for prevention of adhesion formation in rats. Arch Gynecol Obstet 276(4):355–359PubMedView ArticleGoogle Scholar
  18. Baca B, Boler DE, Onur E et al (2007) Icodextrin and Seprafilm do not interfere with colonic anastomosis in rats. Eur Surg Res 39(5):318–323PubMedView ArticleGoogle Scholar
  19. Bahadir I, Oncel M, Kement M, Sahip Y (2007) Intra-abdominal use of taurolidine or heparin as alternative products to an antiadhesive barrier (Seprafilm) in adhesion prevention: an experimental study on mice. Dis Colon Rectum 50(12):2209–2214PubMedView ArticleGoogle Scholar
  20. Kaptanoglu L, Kucuk HF, Yegenoglu A et al (2008) Effects of Seprafilm and heparin in combination on intra-abdominal adhesions. Eur Surg Res 41(2):203–207PubMedView ArticleGoogle Scholar
  21. Altuntas YE, Kement M, Oncel M, Sahip Y, Kaptanoglu L (2008) The effectiveness of hyaluronan-carboxymethylcellulose membrane in different severity of adhesions observed at the time of relaparotomies: an experimental study on mice. Dis Colon Rectum 51(10):1562–1565PubMedView ArticleGoogle Scholar
  22. Emre A, Akin M, Isikgonul I, Yuksel O, Anadol AZ, Cifter C (2009) Comparison of intraperitoneal honey and sodium hyaluronate-carboxymethylcellulose (Seprafilm) for the prevention of postoperative intra-abdominal adhesions. Clin (Sao Paulo) 64(4):363–368Google Scholar
  23. Ersoy E, Ozturk V, Yazgan A, Ozdogan M, Gundogdu H (2009) Comparison of the two types of bioresorbable barriers to prevent intra-abdominal adhesions in rats. J Gastrointest Surg 13(2):282–286PubMedView ArticleGoogle Scholar
  24. Irkorucu O, Ferahkose Z, Memis L, Ekinci O, Akin M (2009) Reduction of postsurgical adhesions in a rat model: a comparative study. Clin (Sao Paulo) 64(2):143–148Google Scholar
  25. Lim R, Morrill J, Lynch R et al (2009) Practical limitations of bioresorbable membranes in the prevention of intra-abdominal adhesions. J Gastrointest Surg 13(1):35–41, discussion 41-32PubMedView ArticleGoogle Scholar
  26. Rajab TK, Wallwiener M, Planck C, Brochhausen C, Kraemer B, Wallwiener CW (2010) A direct comparison of Seprafilm, adept, intercoat, and spraygel for adhesion prophylaxis. J Surg Res 161(2):246–249PubMedView ArticleGoogle Scholar
  27. Falabella CA, Melendez MM, Weng L, Chen W (2010) Novel macromolecular crosslinking hydrogel to reduce intra-abdominal adhesions. J Surg Res 159(2):772–778PubMedView ArticleGoogle Scholar
  28. Wiseman DM, Meidler R, Lyahovetsky Y, Kurman E, Horn S, Nur I (2010) Evaluation of a fibrin preparation containing tranexamic acid (Adhexil) in a rabbit uterine horn model of adhesions with and without bleeding and in a model with two surgical loci. Fertil Steril 93(4):1045–1051PubMedView ArticleGoogle Scholar
  29. Lalountas MA, Ballas KD, Skouras C et al (2010) Preventing intraperitoneal adhesions with atorvastatin and sodium hyaluronate/carboxymethylcellulose: a comparative study in rats. Am J Surg 200(1):118–123PubMedView ArticleGoogle Scholar
  30. Lo HY, Kuo HT, Huang YY (2010) Application of polycaprolactone as an anti-adhesion biomaterial film. Artif Organs 34(8):648–653PubMedGoogle Scholar
  31. Kement M, Censur Z, Oncel M, Buyukokuroglu ME, Gezen FC (2010) Heparin for adhesion prevention: comparison of three different dosages with Seprafilm in a murine model. Int J Surg 9:225–228PubMedView ArticleGoogle Scholar
  32. Durmus AS (2010) Effect of Seprafilm on prevention of intraabdominal adhesions in rats. Indian Vet J 87:816–817Google Scholar
  33. Attar R, Yildirim G, Kumbak B, Ficicioglu C, Demirbag S, Yesildaglar N (2011) Efficacy of melatonin and hyaluronate/carboxymethylcellulose membrane in preventing adhesion reformation following adhesiolysis in a rat uterine model. J Obstet Gynaecol Res 37(2):125–131PubMedView ArticleGoogle Scholar
  34. Baptista ML, Bonsack ME, Delaney JP (2000) Seprafilm reduces adhesions to polypropylene mesh. Surgery 128(1):86–92PubMedView ArticleGoogle Scholar
  35. van Oosterom F, van Lanschot J, Oosting J, Obertop H (2000) Hyaluronic acid/carboxymethylcellulose membrane surrounding an intraperitoneal or subcutaneous jejunojejunostomy in rats. Eur J Surg 166(8):654–658PubMedView ArticleGoogle Scholar
  36. Erturk S, Yuceyar S, Temiz M et al (2003) Effects of hyaluronic acid–carboxymethylcellulose antiadhesion barrier on ischemic colonic anastomosis: an experimental study. Dis Colon Rectum 46(4):529–534PubMedView ArticleGoogle Scholar
  37. Medina M, Paddock HN, Connolly RJ, Schwaitzberg SD (1995) Novel antiadhesion barrier does not prevent anastomotic healing in a rabbit model. J Investig Surg 8(3):179–186View ArticleGoogle Scholar
  38. Tzianabos AO, Cisneros RL, Gershkovich J et al (1999) Effect of surgical adhesion reduction devices on the propagation of experimental intra-abdominal infection. Arch Surg 134(11):1254–1259PubMedView ArticleGoogle Scholar
  39. Oncel M, Remzi FH, Senagore AJ, Connor JT, Fazio VW (2003) Comparison of a novel liquid (Adcon-P) and a sodium hyaluronate and carboxymethylcellulose membrane (Seprafilm) in postsurgical adhesion formation in a murine model. Dis Colon Rectum 46(2):187–191PubMedView ArticleGoogle Scholar
  40. Oncel M, Remzi FH, Senagore AJ, Connor JT, Fazio VW (2004) Application of Adcon-P or Seprafilm in consecutive laparotomies using a murine model. Am J Surg 187(2):304–308PubMedView ArticleGoogle Scholar
  41. Ustun C, Kocak I, Akpolat I (2000) Effects of Seprafilm (sodium hyaluranate-based bioresorbable), Sepracoat (0.4 % hyaluronic acid), and Ringer’s lactate on the prevention of postsurgical adhesion formation in rat models. J Obstet Gynaecol 20(1):78–80PubMedView ArticleGoogle Scholar
  42. Eroglu A, Demirci S, Kurtman C, Akbay A, Eroglu N (2001) Prevention of intra-abdominal adhesions by using Seprafilm in rats undergoing bowel resection and radiation therapy. Colorectal Dis 3(1):33–37PubMedView ArticleGoogle Scholar
  43. Ghellai AM, Stucchi AF, Lynch DJ, Skinner KC, Colt MJ, Becker JM (2000) Role of a hyaluronate-based membrane in the prevention of peritonitis-induced adhesions. J Gastrointest Surg 4(3):310–315PubMedView ArticleGoogle Scholar
  44. Adanali G, Verdi M, Tuncel A, Erdogan B, Kargi E (2003) Effects of hyaluronic acid–carboxymethylcellulose membrane on extraneural adhesion formation and peripheral nerve regeneration. J Reconstr Microsurg 19(1):29–36PubMedView ArticleGoogle Scholar
  45. Sasaki T, Shimura H, Tanaka T, Nakashima K, Matsuo K, Ikeda S (2004) Protection of trocar sites from gallbladder cancer implantation by sodium hyaluronate carboxymethylcellulose-based bioresorbable membrane (Seprafilm) in a murine model [corrected]. Surg Endosc 18(2):246–251PubMedView ArticleGoogle Scholar
  46. Hubbard SC, Burns JW (2002) Effects of a hyaluronan-based membrane (Seprafilm) on intraperitoneally disseminated human colon cancer cell growth in a nude mouse model. Dis Colon Rectum 45(3):334–341, discussion 341-334PubMedView ArticleGoogle Scholar
  47. Underwood RA, Wu JS, Wright MP et al (1999) Sodium hyaluronate carboxymethylcellulose-based bioresorbable membrane (Seprafilm)—does it affect tumor implantation at abdominal wound sites? Dis Colon Rectum 42(5):614–618, discussion 618-619PubMedView ArticleGoogle Scholar
  48. Pucciarelli S, Codello L, Rosato A, Del Bianco P, Vecchiato G, Lise M (2003) Effect of antiadhesive agents on peritoneal carcinomatosis in an experimental model. Br J Surg 90(1):66–71PubMedView ArticleGoogle Scholar
  49. Mitchell JD, Lee R, Neya K, Vlahakes GJ (1994) Reduction in experimental pericardial adhesions using a hyaluronic acid bioabsorbable membrane. Eur J Cardiothorac Surg 8(3):149–152PubMedView ArticleGoogle Scholar
  50. Mueller XM, Tevaearai HT, Augstburger M, Burki M, von Segesser LK (1999) Prevention of pericardial adhesions with a bioresorbable membrane. Swiss Surg 5(1):23–26PubMedView ArticleGoogle Scholar
  51. Ballore L, Orru F, Nicolini F, Contini SA, Galletti G, Gherli T (2000) Experimental results of the use of hyaluronic acid based materials (CV Seprafilm and CV Sepracoat) in postoperative pericardial adhesions. Acta Biomed Ateneo Parmense 71(5):159–166PubMedGoogle Scholar
  52. Karakurum G, Buyukbebeci O, Kalender M, Gulec A (2003) Seprafilm interposition for preventing adhesion formation after tenolysis. An experimental study on the chicken flexor tendons. J Surg Res 113(2):195–200PubMedView ArticleGoogle Scholar
  53. Garlick D, Diters R, Magee T, Joyce J, O'Callaghan M, Skrabut E (1999) Safety Evaluation of Seprafilm(R) bioresorbable membrane in synovial joints of New Zealand White rabbits. Toxicol Pathol 27(6):700Google Scholar
  54. Kasimcan MO, Bakar B, Aktas S, Alhan A, Yilmaz M (2011) Effectiveness of the biophysical barriers on the peridural fibrosis of a postlaminectomy rat model: an experimental research. Injury 42(8):778–781PubMedView ArticleGoogle Scholar
  55. Topsakal C, Akpolat N, Erol FS et al (2004) Seprafilm superior to Gore-Tex in the prevention of peridural fibrosis. J Neurosurg 101(2):295–302PubMedView ArticleGoogle Scholar
  56. Dogan S, Taskapilioglu O, Sahin S, Korfali E (2009) The effects of Seprafilm and Interceed TC7 on epidural fibrosis in a rat hemilaminectomy model. Neurosurg Q 19(3):190–195View ArticleGoogle Scholar
  57. Ozkan SB, Kir E, Culhaci N, Dayanir V (2004) The effect of Seprafilm on adhesions in strabismus surgery—an experimental study. J Aapos 8(1):46–49PubMedView ArticleGoogle Scholar
  58. Konakci E, Koyuncu M, Unal R, Tekat A, Uyar M (2004) Repair of subtotal tympanic membrane perforations with Seprafilm. J Laryngol Otol 118(11):862–865PubMedView ArticleGoogle Scholar
  59. Gago LA, Saed GM, Wang RX, Kruger M, Diamond MP (2003) Effects of oxidized regenerated cellulose on the expression of extracellular matrix and transforming growth factor-beta1 in human peritoneal fibroblasts and mesothelial cells. Am J Obstet Gynecol 189(6):1620–1625, discussion 1625-1626PubMedView ArticleGoogle Scholar
  60. Reijnen MM, Meis JF, Postma VA, van Goor H (1999) Prevention of intra-abdominal abscesses and adhesions using a hyaluronic acid solution in a rat peritonitis model. Arch Surg 134(9):997–1001PubMedView ArticleGoogle Scholar
  61. Uchida K, Urata H, Mohri Y, Inoue M, Miki C, Kusunoki M (2005) Seprafilm does not aggravate intraperitoneal septic conditions or evoke systemic inflammatory response. Surg Today 35(12):1054–1059PubMedView ArticleGoogle Scholar
  62. Otake K, Uchida K, Yoshiyama S et al (2008) Effects of a hyaluronate-carboxymethylcellulose membrane (Seprafilm) on human polymorphonuclear neutrophil functions. J Surg Res 149(2):243–249PubMedView ArticleGoogle Scholar
  63. Naito Y, Shin'oka T, Hibino N, Matsumura G, Kurosawa H (2008) A novel method to reduce pericardial adhesion: a combination technique with hyaluronic acid biocompatible membrane. J Thorac Cardiovasc Surg 135(4):850–856PubMedView ArticleGoogle Scholar
  64. Bel A, Kachatryan L, Bruneval P et al (2009) A new absorbable collagen membrane to reduce adhesions in cardiac surgery. Interact Cardiovasc Thorac Surg 10(2):213–216PubMedView ArticleGoogle Scholar
  65. Galena D, Grunenwald D, Validire P, Borenstein N. Effectiveness of a new bioabsorbable barrier in preventing pleural adhesions: a prospective, randomized, experimental study. Paper presented at: The 83rd Annual Meeting of the American Association for Thoracic Surgery, 2003; Boston, MAGoogle Scholar
  66. Yilmaz O, Genc A, Taneli F, Demireli P, Deliaga H, Taneli C (2007) Assessment of the efficacy of absorbable adhesion barriers on dissection in esophagus operations. Int J Pediatr Otorhinolaryngol 71(3):409–414PubMedView ArticleGoogle Scholar
  67. Bahcivan M, Yucel S, Kefeli M, Gol MK, Can B, Keceligil HT (2008) Inhibition of vein graft intimal hyperplasia by periadventitial application of hyaluronic acid–carboxymethyl cellulose: an experimental study. Scand Cardiovasc J 42(2):161–165PubMedView ArticleGoogle Scholar
  68. Yilmaz E, Avci M, Bulut M, Kelestimur H, Karakurt L, Ozercan I (2010) The effect of Seprafilm on adhesion formation and tendon healing after flexor tendon repair in chicken. Orthopedics 164–170Google Scholar
  69. Liu Y, Skardal A, Shu XZ, Prestwich GD (2008) Prevention of peritendinous adhesions using a hyaluronan-derived hydrogel film following partial-thickness flexor tendon injury. J Orthop Res 26(4):562–569PubMedView ArticleGoogle Scholar
  70. Magill CK, Tuffaha SH, Yee A et al (2009) The short- and long-term effects of Seprafilm on peripheral nerves: a histological and functional study. J Reconstr Microsurg 25(6):345–354PubMedView ArticleGoogle Scholar
  71. Takeuchi K, Nakazawa M, Yamazaki H et al (2009) Solid hyaluronic acid film and the prevention of postoperative fibrous scar formation in experimental animal eyes. Arch Ophthalmol 127(4):460–464PubMedView ArticleGoogle Scholar
  72. Tsurumaru N, Arai M, Teruya K, Sueda J, Yamakawa R (2009) Seprafilm as a new antifibrotic agent following trabeculectomy in rabbit eyes. Jpn J Ophthalmol 53(2):164–170PubMedView ArticleGoogle Scholar
  73. Teruya K, Sueda J, Arai M et al (2009) Patching retinal breaks with Seprafilm in experimental rhegmatogenous retinal detachment of rabbit eyes. Eye 23(12):2256–2259PubMedView ArticleGoogle Scholar
  74. Jang CH, Park H, Cho YB, Choi CH (2008) The effect of anti-adhesive packing agents in the middle ear of guinea pig. Int J Pediatr Otorhinolaryngol 72(11):1603–1608PubMedView ArticleGoogle Scholar
  75. Tsapanos VS, Stathopoulou LP, Papathanassopoulou VS, Tzingounis VA (2002) The role of Seprafilm bioresorbable membrane in the prevention and therapy of endometrial synechiae. J Biomed Mater Res 63(1):10–14PubMedView ArticleGoogle Scholar
  76. van der Linden J, Duvernoy O, Hadjinikolaou L, Bengtsson L (2001) Does hyaluronate prevent postoperative retro-sternal adhesions in coronary surgery?—preliminary results. Eur J Cardiothorac Surg 19(6):949–950PubMedView ArticleGoogle Scholar
  77. Sanders RJ, Hammond SL, Rao NM (2007) Observations on the use of Seprafilm on the brachial plexus in 249 operations for neurogenic thoracic outlet syndrome. Hand (N Y) 2(4):179–183Google Scholar
  78. Koyuncu M, Atmaca S, Ceyhan M, Erol Y (2009) Internal jugular vein performance after functional neck dissection and the role of Seprafilm. Trakya Universitesi Tip Fakultesi Dergisi 26(4):322–325Google Scholar
  79. Filler AG, Haynes J, Jordan SE et al (2005) Sciatica of nondisc origin and piriformis syndrome: diagnosis by magnetic resonance neurography and interventional magnetic resonance imaging with outcome study of resulting treatment. J Neurosurg Spine 2(2):99–115PubMedView ArticleGoogle Scholar
  80. Assaf A (1999) Seprafilm in repeated strabismus surgery to reduce surgical scarring. In: Lennerstrand G (ed) Advances in Strabismology. Aeolus, Buren, pp 377–380Google Scholar
  81. Taban M, Nakra T, Mancini R, Douglas RS, Goldberg RA (2009) Orbital wall fracture repair using Seprafilm. Ophthal Plast Reconstr Surg 25(3):211–214PubMedView ArticleGoogle Scholar
  82. Shibata M, Sugiyama T, Kojima S, Nagamatsu S, Hayashida M, Ikeda T (2010) A case of neovascular glaucoma treated by trabeculectomy with adjunct use of Seprafilm. Jpn J Clin Opthalmol 64(12):1891–1895Google Scholar
  83. Caylan R, Bektas D (2007) Preservation of the mastoid aeration and prevention of mastoid dimpling in chronic otitis media with cholesteatoma surgery using hyaluronate-based bioresorbable membrane (Seprafilm). Eur Arch Otorhinolaryngol 264(4):377–380PubMedView ArticleGoogle Scholar
  84. Ichinose T, Uda T, Kusakabe T, Murata K, Sakaguchi M (2007) Effectiveness of antiadhesion barriers in preventing adhesion for external decompression and subsequent cranioplasty. No Shinkei Geka 35(2):151–154PubMedGoogle Scholar

Copyright

© The Author(s) 2012